Equity · Healthcare
BBIO
NASDAQBridgeBio Pharma (BBIO)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for BBIO to draw a line in its place.
- Market cap
- 14.5B USD
- Revenue, year to Dec 2025
- 502.1M USD
- EPS, diluted, year to Dec 2025
- −3.78 USD
- 52-week range
- 61.33 USD – 90 USD
- Avg volume
- 194.1K
as of Nov 6, 2026
Have BridgeBio Pharma (BBIO) insiders bought or sold shares recently?
BBIO has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 30 October 2026.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 30 Oct 2026 | Apuli MaricelChief Accounting Officer | Sell | 2,000 | 146K USD |
| 17 Sep 2026 | Kumar NeilChief Executive Officer | Sell | 10,000 | 691K USD |
| 19 Aug 2026 | Kumar NeilChief Executive Officer | Sell | 10,000 | 840K USD |
| 18 Aug 2026 | Kumar NeilChief Executive Officer | Sell | 34,980 | 2.9M USD |
| 30 Jul 2026 | Apuli MaricelChief Accounting Officer | Sell | 2,000 | 160K USD |
| 09 Jul 2026 | Cook Jennifer E.Director | Sell | 148,589 | 13.2M USD |
| 09 Jul 2026 | Ellis AndreaDirector | Sell | 17,167 | 1.4M USD |
| 24 Jun 2026 | Cook Jennifer E.Director | Sell | 37,167 | 2.6M USD |
| 23 Jun 2026 | Valantine HannahDirector | Sell | 2,196 | 151K USD |
| 23 Jun 2026 | Cook Jennifer E.Director | Sell | 2,196 | 151K USD |
| 22 Jun 2026 | Valantine HannahDirector | Sell | 2,808 | 191K USD |
| 15 Jun 2026 | Cook Jennifer E.Director | Sell | 90,240 | 6.0M USD |
| Sold | 26 open-market sales | 804,689 | $59.05M |
Showing the 12 most recent of 26 open-market trades in this window. The figures above count all of them.
32 other filings: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 16 Aug 2026 | Apuli MaricelChief Accounting Officer | Tax withheld | 4,714 | 376K USD |
| 16 Aug 2026 | Kumar NeilChief Executive Officer | Option exercise | 71,217 | |
| 16 Aug 2026 | Kumar NeilChief Executive Officer | Tax withheld | 36,237 | 2.9M USD |
| 16 Aug 2026 | Trimarchi ThomasPresident and CFO | Tax withheld | 22,781 | 1.8M USD |
| 09 Jul 2026 | Cook Jennifer E.Director | Option exercise | 148,589 | 3.7M USD |
| 09 Jul 2026 | Ellis AndreaDirector | Option exercise | 17,167 | 288K USD |
| 24 Jun 2026 | Cook Jennifer E.Director | Option exercise | 37,167 | 457K USD |
| 22 Jun 2026 | AGUIAR ERICDirector | Award | 3,990 | |
| 22 Jun 2026 | Satvat Ali J.Director | Award | 3,990 | |
| 22 Jun 2026 | Dachille Douglas A.Director | Award | 3,990 | |
| 22 Jun 2026 | MCCORMICK FRANKDirector | Award | 3,990 | |
| 22 Jun 2026 | MOMTAZEE JAMES CDirector | Award | 3,990 |
Showing the 12 most recent of 32 compensation filings in this window. The figures above count all of them.
Which funds hold BridgeBio Pharma (BBIO)?
1 of the 45 institutional funds we track reported a BridgeBio Pharma position for the quarter ended 30 Sep 2026 — a combined 22.9M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 348,675 | 22.9M USD | +1.0% |
Have members of Congress traded BridgeBio Pharma (BBIO)?
The most recent congressional trade disclosed in BridgeBio Pharma is a sale by Gilbert Ray Cisneros, Jr. (house, CA), dated 29 Sep 2026.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 29 Sep 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Sale | 1K USD–15K USD | 13 days |
| 11 May 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 28 days |
| 19 Mar 2026 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 19 days |
| 22 Sep 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 18 days |
| 08 Aug 2025 | Gilbert Ray Cisneros, Jr.house · Democrat–CA | Purchase | 1K USD–15K USD | 35 days |
What has been filed or recorded for BridgeBio Pharma (BBIO)?
The filings we hold for BridgeBio Pharma, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS −0.42 USD | Revenue $353M |
| 30 Sep 2026 | Financials | Total assets | 2.2B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | −1.7B USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.78 USD | Revenue $244M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.84 USD | Revenue $195M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.78 USD | Revenue $502M |
| 31 Dec 2025 | Financials | Revenue | 502.1M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income to common shareholders | −724.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.78 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.95 USD | Revenue $121M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.95 USD | Revenue $111M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.88 USD | Revenue $117M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.88 USD | Revenue $222M |
BridgeBio Pharma (BBIO): frequently asked questions
What is BridgeBio Pharma’s market cap?
BridgeBio Pharma is worth 14.5B USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is BridgeBio Pharma’s revenue?
BridgeBio Pharma reported revenue of 502.1M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have BridgeBio Pharma insiders bought or sold shares recently?
No BridgeBio Pharma insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 30 Oct 2026 (SEC Form 4). See Insiders
Which funds own BridgeBio Pharma?
1 of the 45 funds we track reported a BridgeBio Pharma position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
Have members of Congress traded BridgeBio Pharma?
Yes. 5 trades in BridgeBio Pharma appear in the congressional disclosures we hold; the latest is a sale by Gilbert Ray Cisneros, Jr. (House, CA) dated 29 Sep 2026, filed 12 Oct 2026. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did BridgeBio Pharma last report earnings?
BridgeBio Pharma last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.42 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings